Javascript must be enabled to continue!
Efficacy and safety of omega-3-enriched lickable treats as adjunctive therapy for feline chronic gingivostomatitis: A randomized controlled trial
View through CrossRef
Background and Aim: Feline chronic gingivostomatitis (FCGS) is a debilitating inflammatory condition of the oral cavity in cats, associated with chronic pain, salivation, halitosis, and reduced quality of life. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have known anti-inflammatory properties and may offer a supportive treatment option. This study aimed to evaluate the safety and clinical efficacy of two marine-derived n-3 PUFA sources – krill oil and green-lipped mussel (GLM) oil – administered through lickable cat treats in cats with FCGS.
Materials and Methods: Sixteen FCGS cats were randomized into three double-blinded treatment groups to receive daily lickable treats: Control (no n-3 PUFA), krill oil (100 mg), or GLM oil (100 mg) for 28 days. Clinical outcomes (stomatitis and pain scores, halitosis, and salivation) were assessed on days 0, 14, and 28 by veterinarians. Owner-reported outcomes and inflammatory cytokine levels (interleukin 6, interleukin 1 beta, and interferon-gamma) were also evaluated.
Results: Both krill and GLM oil treatments were well-tolerated, with no adverse changes in body weight, hematological, or biochemical parameters. Mean stomatitis and pain scores showed a non-significant downward trend in all groups. Halitosis and salivation improved in seven cats, particularly in the GLM and control groups. Owner-reported improvement was observed in 10 of 16 cats, with the highest in the krill oil group (75%). Cytokine levels demonstrated high variability and no statistically significant changes. No significant differences were observed between the n-3 PUFA sources.
Conclusion: Daily administration of n-3 PUFA-enriched cat treats is safe and may provide mild clinical benefit in cats with FCGS, particularly in alleviating oral discomfort. While no significant differences were found between krill and GLM oils, both formulations were palatable and suitable as adjunctive therapy. Further research with larger cohorts, extended durations, and sensitive scoring systems is warranted to optimize treatment protocols.
Keywords: adjuvant therapy, cat oral health, cytokines, feline chronic gingivostomatitis, green-lipped mussel oil, inflammation, krill oil, nutraceuticals, omega-3 polyunsaturated fatty acids, lickable cat treat.
Title: Efficacy and safety of omega-3-enriched lickable treats as adjunctive therapy for feline chronic gingivostomatitis: A randomized controlled trial
Description:
Background and Aim: Feline chronic gingivostomatitis (FCGS) is a debilitating inflammatory condition of the oral cavity in cats, associated with chronic pain, salivation, halitosis, and reduced quality of life.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have known anti-inflammatory properties and may offer a supportive treatment option.
This study aimed to evaluate the safety and clinical efficacy of two marine-derived n-3 PUFA sources – krill oil and green-lipped mussel (GLM) oil – administered through lickable cat treats in cats with FCGS.
Materials and Methods: Sixteen FCGS cats were randomized into three double-blinded treatment groups to receive daily lickable treats: Control (no n-3 PUFA), krill oil (100 mg), or GLM oil (100 mg) for 28 days.
Clinical outcomes (stomatitis and pain scores, halitosis, and salivation) were assessed on days 0, 14, and 28 by veterinarians.
Owner-reported outcomes and inflammatory cytokine levels (interleukin 6, interleukin 1 beta, and interferon-gamma) were also evaluated.
Results: Both krill and GLM oil treatments were well-tolerated, with no adverse changes in body weight, hematological, or biochemical parameters.
Mean stomatitis and pain scores showed a non-significant downward trend in all groups.
Halitosis and salivation improved in seven cats, particularly in the GLM and control groups.
Owner-reported improvement was observed in 10 of 16 cats, with the highest in the krill oil group (75%).
Cytokine levels demonstrated high variability and no statistically significant changes.
No significant differences were observed between the n-3 PUFA sources.
Conclusion: Daily administration of n-3 PUFA-enriched cat treats is safe and may provide mild clinical benefit in cats with FCGS, particularly in alleviating oral discomfort.
While no significant differences were found between krill and GLM oils, both formulations were palatable and suitable as adjunctive therapy.
Further research with larger cohorts, extended durations, and sensitive scoring systems is warranted to optimize treatment protocols.
Keywords: adjuvant therapy, cat oral health, cytokines, feline chronic gingivostomatitis, green-lipped mussel oil, inflammation, krill oil, nutraceuticals, omega-3 polyunsaturated fatty acids, lickable cat treat.
Related Results
A-198 Acute Effects of a Single Moderate-intensity Exercise on Omega-3 and Omega-6 Metabolic Pathway Using Whole Blood Lipidomics
A-198 Acute Effects of a Single Moderate-intensity Exercise on Omega-3 and Omega-6 Metabolic Pathway Using Whole Blood Lipidomics
Abstract
Background
Omega-3 fatty acid supplementation can reduce muscle soreness and maintain muscle function following eccentr...
Многомодовые перепутанные состояния в связанных оптических параметрических взаимодействиях и их применения в телепортации
Многомодовые перепутанные состояния в связанных оптических параметрических взаимодействиях и их применения в телепортации
Des états intriqués créés dans les interactions paramétriques optiques et leurs applications en téléportation
La thèse est consacrée au développement de la théorie ...
Abstract P290: Dietary and Serum Omega-6 and Omega-3 Fatty Acids Are Associated With Physical and Metabolic Dysfunction in Chronic Stroke Survivors
Abstract P290: Dietary and Serum Omega-6 and Omega-3 Fatty Acids Are Associated With Physical and Metabolic Dysfunction in Chronic Stroke Survivors
Background:
Higher dietary intake of omega-6/omega-3 ratios is associated with reduced physical functioning in older adults, but is not well documented in chronic strok...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial
Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial
Abstract
Background
Hypertriglyceridemia is a modifiable risk factor for cardiovascular disease, and while omega-3 fatty ...
Omega-6/omega-3 ratio serum, omega-3 index, and hs-CRP serum in obese adolescents aged 16-18 years
Omega-6/omega-3 ratio serum, omega-3 index, and hs-CRP serum in obese adolescents aged 16-18 years
The incidence of obesity in the world has more than tripled between 1975 and 2016.
International organizations and many researchers continue to look for causes of obesity.
The expe...

